edd/Lancet Infect Dis

COVID-19 mortality in Africa and Asia - Authors' reply.Bejon P, Agweyu A, Oyier I, Hamaluba M, Kamuya D, Kinyanjui S, Barasa E
Lancet Infect Dis, (2025). :

Rethinking the evidence on COVID-19 in Africa.Bejon P, Agweyu A, Ochola-Oyier LI, Hamaluba M, Kamuya D, Kinyanjui S, Barasa E
Lancet Infect Dis, (2025). 25:S1473-3099

Effect of mass campaigns with full and fractional doses of pneumococcal conjugate vaccine (Pneumosil) on the reduction of nasopharyngeal pneumococcal carriage in Niger: a three-arm, open-label, cluster-randomised trial.Coldiron ME, Soumana I, Baudin E, Langendorf C, Mamiafo Tchoula C, Brah S, Karani A, Gallagher KE, Kagucia EW, Scott JAG, Grais RF
Lancet Infect Dis, (2025). 24:S1473-3099

Malaria prophylaxis in sickle cell anaemia: some answers, more questions.Williams TN, Ware RE
Lancet Infect Dis, (2024). 24:S1473-3099

Serotype distribution of remaining invasive pneumococcal disease after extensive use of ten-valent and 13-valent pneumococcal conjugate vaccines (the PSERENADE project): a global surveillance analysis.Garcia Quesada M, Peterson ME, Bennett JC, Hayford K, Zeger SL, Yang Y, Hetrich MK, Feikin DR, Cohen AL, von Gottberg A, van der Linden M, van Sorge NM, de Oliveira LH, de Miguel S, Yildirim I, Vestrheim DF, Verani JR, Varon E, Valentiner-Branth P, Tzanakaki G, Sinkovec Zorko N, Setchanova LP, Serhan F, Scott KJ, Scott JA, Savulescu C, Savrasova L, Reyburn R, Oishi K, Nuorti JP, Napoli D, Mwenda JM, Munoz-Almagro C, Morfeldt E, McMahon K, McGeer A, Mad'arova L, Mackenzie GA, Eugenia Leon M, Ladhani SN, Kristinsson KG, Kozakova J, Kleynhans J, Klein NP, Kellner JD, Jayasinghe S, Ho PL, Hilty M, Harker-Jones MA, Hammitt LL, Grgic-Vitek M, Gilkison C, Gierke R, French N, Diawara I, Desmet S, De Wals P, Dalby T, Dagan R, Corcoran M, Colzani E, Chanto Chacon G, Castilla J, Camilli R, Ang M, Ampofo K, Almeida SCG, Alarcon P, O'Brien KL, Deloria Knoll M, Pserenade Team
Lancet Infect Dis, (2024). 24:445-456

Global impact of ten-valent and 13-valent pneumococcal conjugate vaccines on invasive pneumococcal disease in all ages (the PSERENADE project): a global surveillance analysis.Bennett JC, Deloria Knoll M, Kagucia EW, Garcia Quesada M, Zeger SL, Hetrich MK, Yang Y, Herbert C, Ogyu A, Cohen AL, Yildirim I, Winje BA, von Gottberg A, Viriot D, van der Linden M, Valentiner-Branth P, Suga S, Steens A, Skoczynska A, Sinkovec Zorko N, Scott JA, Savulescu C, Savrasova L, Sanz JC, Russell F, Ricketson LJ, Puentes R, Nuorti JP, Mereckiene J, McMahon K, McGeer A, Mad'arova L, Mackenzie GA, MacDonald L, Lepp T, Ladhani SN, Kristinsson KG, Kozakova J, Klein NP, Jayasinghe S, Ho PL, Hilty M, Heyderman RS, Hasanuzzaman M, Hammitt LL, Guevara M, Grgic-Vitek M, Gierke R, Georgakopoulou T, Galloway Y, Diawara I, Desmet S, De Wals P, Dagan R, Colzani E, Cohen C, Ciruela P, Chuluunbat U, Chan G, Camilli R, Bruce MG, Brandileone MC, Bigogo G, Ampofo K, O'Brien KL, Feikin DR, Hayford K, Pserenade Team
Lancet Infect Dis, (2024). 25:457-470

The long-term efficacy of a respiratory syncytial virus vaccine for older adults.Sande CJ
Lancet Infect Dis, (2024). 24:941-942

Changes in the global hospitalisation burden of respiratory syncytial virus in young children during the COVID-19 pandemic: a systematic analysis.Cong B, Ko� U, Bandeira T, Bassat Q, Bont L, Chakhunashvili G, Cohen C, Desnoyers C, Hammitt LL, Heikkinen T, Huang QS, Marki? J, Mira-Iglesias A, Moyes J, Nokes DJ, Ploin D, Seo E, Singleton R, Wolter N, Fu Yung C, Zar HJ, Feikin DR, Sparrow EG, Nair H, Li Y
Lancet Infect Dis, (2023). S1473-3099:00630-8

Mortality associated with third-generation cephalosporin resistance in Enterobacterales bloodstream infections at eight sub-Saharan African hospitals (MBIRA): a prospective cohort study.Aiken AM, Rehman AM, de Kraker MEA, Madrid L, Kebede M, Labi AK, Obeng-Nkrumah N, Nyamwaya B, Kagucia E, Cocker D, Kawaza K, Lester R, Iregbu KC, Medugu N, Nwajiobi-Princewill PI, Dramowski A, Sonda T, Hemed A, Fwoloshi S, Ojok D, Scott JAG, Whitelaw A
Lancet Infect Dis, (2023). S1473-3099:00233-5

Population immunity to pneumococcal serotypes in Kilifi, Kenya, before and 6 years after the introduction of PCV10 with a catch-up campaign: an observational study of cross-sectional serosurveys.Gallagher KE, Adetifa IMO, Mburu C, Bottomley C, Akech D, Karani A, Pearce E, Wang Y, Kagucia EW, Goldblatt D, Hammitt LL, Scott JAG
Lancet Infect Dis, (2023). S1473-3099:00206-2

Safety of age-dosed, single low-dose primaquine in children with glucose-6-phosphate dehydrogenase deficiency who are infected with Plasmodium falciparum in Uganda and the Democratic Republic of the Congo: a randomised, double-blind, placebo-controlled, non-inferiority trial.Taylor WR, Olupot-Olupot P, Onyamboko MA, Peerawaranun P, Weere W, Namayanja C, Onyas P, Titin H, Baseke J, Muhindo R, Kayembe DK, Ndjowo PO, Basara BB, Bongo GS, Okalebo CB, Abongo G, Uyoga S, Williams TN, Taya C, Dhorda M, Tarning J, Dondorp AM, Waithira N, Fanello C, Maitland K, Mukaka M, Day NJP
Lancet Infect Dis, (2022). 23:471-483

Respiratory syncytial virus prevention within reach: the vaccine and monoclonal antibody landscape.Mazur NI, Terstappen J, Baral R, Bardaji A, Beutels P, Buchholz UJ, Cohen C, Crowe JE, Cutland CL, Eckert L, Feikin D, Fitzpatrick T, Fong Y, Graham BS, Heikkinen T, Higgins D, Hirve S, Klugman KP, Kragten-Tabatabaie L, Lemey P, Libster R, Lowensteyn Y, Mejias A, Munoz FM, Munywoki PK, Mwananyanda L, Nair H, Nunes MC, Ramilo O, Richmond P, Ruckwardt TJ, Sande C, Srikantiah P, Thacker N, Waldstein KA, Weinberger D, Wildenbeest J, Wiseman D, Zar HJ, Zambon M, Bont L
Lancet Infect Dis, (2022). 23:e2-e21

Safety and long-term immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: a combined open-label, non-randomised stage 1, and a randomised, double-blind, controlled stage 2 trial.Ishola D, Manno D, Afolabi MO, Keshinro B, Bockstal V, Rogers B, Owusu-Kyei K, Serry-Bangura A, Swaray I, Lowe B, Kowuor D, Baiden F, Mooney T, Smout E, Kohn B, Otieno GT, Jusu M, Foster J, Samai M, Deen GF, Larson H, Lees S, Goldstein N, Gallagher KE, Gaddah A, Heerwegh D, Callendret B, Luhn K, Robinson C, Leyssen M, Greenwood B, Douoguih M, Leigh B, Watson-Jones D, EBLstudy group
Lancet Infect Dis, (2022). 22:97-109

Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in children in Sierra Leone: a randomised, double-blind, controlled trial.Afolabi MO, Ishola D, Manno D, Keshinro B, Bockstal V, Rogers B, Owusu-Kyei K, Serry-Bangura A, Swaray I, Lowe B, Kowuor D, Baiden F, Mooney T, Smout E, Kohn B, Otieno GT, Jusu M, Foster J, Samai M, Deen GF, Larson H, Lees S, Goldstein N, Gallagher KE, Gaddah A, Heerwegh D, Callendret B, Luhn K, Robinson C, Greenwood B, Leyssen M, Douoguih M, Leigh B, Watson-Jones D, EBLstudy group
Lancet Infect Dis, (2022). 22:110-122

Implementation strategies for passive respiratory syncytial virus immunisation.Sande CJ
Lancet Infect Dis, (2021). 21:1200-1201

Investment in pneumonia and pneumococcal research.Head MG, Fitchett JR, Newell ML, Scott JAG, Clarke SC, Atun R
Lancet Infect Dis, (2014). 14:1037-1038

Antibiotic resistance needs global solutions.Aiken AM, Allegranzi B, Scott JA, Mehtar S, Pittet D, Grundmann H
Lancet Infect Dis, (2014). 14:550-1

Balancing act: haemoglobinopathies and malaria.Williams TN
Lancet Infect Dis, (2012). 12:427-8